INS and type 1 diabetes mellitus: Canagliflozin in T1D: Rodbard and Henry, who performed research on RCTs by investigating the effects of canagliflozin administered in two doses versus placebo on T1D in trials with a duration of 18 weeks reported similar outcomes in the indices of glycemic efficacy and body weight, as well as reductions in insulin doses and a higher risk of DKA [72,124].